EnteroBiotix

EnteroBiotix is a clinical-stage microbiome therapeutics company developing an orally delivered, full-spectrum microbiome drug for irritable bowel syndrome and other diseases linked to the gastrointestinal tract and the liver.

EBX-102-02 is a high-diversity microbial product formulated as an off-white colour, odourless powder and manufactured using EnteroBiotix's proprietary AMPLA drying technology. Microbiome-modulating approaches such as diet, prebiotics, probiotics, antibiotics and faecal microbiota transplantation have shown benefit in subsets of patients, while their clinical effects have been variable and inconsistent. EnteroBiotix is seeking licensing partners to advance late-stage clinical development and commercialisation of EBX-102-02.